Health ❯ Healthcare

Drug Development

Clinical Trials Clinical Research Regulatory Affairs FDA Approval Regulatory Approval Therapeutics FDA Regulations Pharmaceutical Research Efficacy Studies Combination Therapy Cancer Treatment FDA Approvals GLP-1 Agonists Precision Medicine Generic Drugs Biologics Investigational Drugs Targeted Therapy Oncology Pharmaceuticals Monoclonal Antibodies Research and Development Next-Generation Therapies Rare Diseases Targeted Therapies Antimalarial Drugs Biopharmaceuticals Biotechnology Market Trends Clinical Studies Autoimmune Diseases Innovative Therapies Research Funding Treatment Research Active Pharmaceutical Ingredients AI in Medicine Biosimilars Antifungal Therapy Cancer Drugs Manufacturing Deficiencies Pharmaceutical Companies Marketing Authorization Therapeutic Approaches Orphan Drug Designation Celiac Disease Treatments Drug Approval Immunology Regulatory Approvals GLP-1 Drugs AI in Healthcare Generic Medicines Phase 1 Trials Oncology Drugs Diabetes Treatment Antiviral Drugs GSK Experimental Drugs Therapeutic Interventions Complement Inhibitors Market Access Manufacturing Processes Clinical Applications GLP-1 Receptor Agonists Injectable Therapies Tyrosine Kinase Inhibitors Vaccine Development Nanotechnology Antiviral Therapies Side Effects Non-opioid Therapies Approval Processes Next-Generation Drugs Efficacy Testing Phase 3 Trials Cardiotoxicity New Treatments Zanidatamab Cancer Therapies Weight Loss Medications FDA Approval Process Next Generation Antibiotics Orphan Drugs Market Approval Research Osteoarthritis GLP-1 Medicines B-cell Depletion Therapies R&D Antiretroviral Drugs Personalized Medicine Pharmacokinetics Psychedelic Drugs Antibiotic Discovery Gilead Sciences Eli Lilly Phase 2 Trials Market Competition Phase Studies RNA Therapeutics Novo Nordisk

BioMarin to Acquire Amicus for $4.8 Billion in All-Cash Deal

The buyer outlines cash-plus-debt financing with earnings accretion targeted within a year.

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Stories older than 24h

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

DBV Peanut Allergy Patch Succeeds in Pivotal Phase 3, Setting Up 2026 FDA Filing

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

Study Finds CBD–THC Combination Kills Ovarian Cancer Cells in Lab

Study Finds FDA Pivotal Trials Rarely Reflect U.S. Diversity as Black and Hispanic Enrollment Falls

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

Belite Bio’s Tinlarebant Cuts Stargardt Lesion Growth 36% in Phase 3 Trial

Cryo-EM Study Reveals How Statins Trigger Muscle Damage

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Enlivex Raises $212 Million to Build RAIN Token Treasury, Plans Matteo Renzi Board Appointment